ArticleRheumatology international2026
Validation of the Dudley inflammatory bowel symptom questionnaire for assessing gastrointestinal symptom burden in axial spondyloarthritis.
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lack of association between the Dudley Inflammatory Bowel Symptom Questionnaire and fecal calprotectin in axial spondyloarthritis: a cross-sectional study.Rheumatology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subclinical and overt inflammatory bowel disease (IBD) is frequently observed in patients with axial spondyloarthritis (ax-SpA), traditionally identified through invasive ileocolonoscopic evaluation. Validated non-invasive assessing instruments are therefore needed to facilitate early detection. This study aimed to validate the Turkish version of the Dudley Inflammatory Bowel Symptom Questionnaire (DISQ) as a tool for assessing gastrointestinal symptom burden suggestive of intestinal involvement in patients with axial spondyloarthritis. In this cross-sectional validation study, 174 patients fulfilling the 2009 Assessment of SpondyloArthritis international Society (ASAS) criteria for axial SpA were enrolled. Convergent validity was assessed by examining correlations between DISQ scores and disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), functional status (Bath Ankylosing Spondylitis Functional Index [BASFI]), and health-related quality of life (Short Form-36 [SF-36]). Discriminant validity was evaluated by comparing DISQ scores in patients with and without gastrointestinal symptoms suggestive of IBD. Test–retest reliability was assessed by re-administration of the DISQ after one month. Internal consistency was evaluated using Cronbach’s alpha. DISQ scores demonstrated moderate positive correlations with BASDAI (r = 0.432, p < 0.001) and BASFI (r = 0.248, p = 0.001), and a strong inverse correlation with SF-36 scores (p < 0.001), supporting convergent validity. Patients reporting diarrhea, abdominal pain, oral aphthae, or mucus in stool had significantly higher DISQ scores than those without these symptoms (all p ≤ 0.008), confirming discriminant validity. The Turkish version of the DISQ demonstrated acceptable internal consistency (Cronbach’s α = 0.70) and good test–retest reliability (ICC = 0.76; 95% CI: 0.51–0.82; p < 0.001). The Turkish version of DISQ demonstrates satisfactory validity and reliability as a non-invasive assessment instrument for gastrointestinal symptoms suggestive of bowel inflammation in patients with ax-SpA. Future studies incorporating endoscopic and biomarker-based outcomes are warranted to define clinically meaningful cut-off values and determine its role in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.